Pharma & CDMOKOSDAQ 195940266 approvals109 trials

HK inno.N Corporation

Spun off from CJ CheilJedang in 2014, HK inno.N is a pharmaceutical company built around its GERD drug K-CAB, alongside ETC and H&B businesses.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Spun off from CJ CheilJedang in April 2014 and listed on KOSDAQ in 2021, HK inno.N is a pharmaceutical company acquired by Kolmar Korea in 2018. Its ETC business offers the GERD drug K-CAB (Korea's 30th approved new drug), Lobazet, and Akinzeo, while its H&B business offers Condition, Hutgaesu, and Vionds. It posted 2025 revenue of KRW 1,063.2 billion and operating profit of KRW 110.9 billion, with ETC accounting for 93% of revenue and H&B 7%; K-CAB ranks No. 1 in the peptic ulcer drug market and has expanded into China, the US, India, and South America.

Products & technology

K-CABGERD (gastroesophageal reflux disease) treatment
Lobazet
Akinzeo
ConditionHangover relief beverage (H&B business)
HutgaesuBeverage (H&B business)
ViondsCosmetics brand (H&B business)

Regulatory approvals

data.go.kr

258 Korean MFDS drug approvals · 1963–2026 / 8 Korean MFDS device approvals · 1999–2013

MFDS drugPeraMix Inj2026-08-24
Drug · Prescription · Approval202602443
MFDS drugLixien. 15mg tab2026-04-13
Drug · Prescription · Approval202601037
MFDS drugLixien. 30mg tab2026-04-13
Drug · Prescription · Approval202601038
MFDS drugLixien. 60mg tab2026-04-13
Drug · Prescription · Approval202601039
MFDS drugDenbrayce Injection2026-02-04
Drug · Prescription · Approval202600307
MFDS drugIzambia Pre-filled syringe2026-02-04
Drug · Prescription · Approval202600308
MFDS drugPlasma Solution D Inj.2025-12-15
Drug · Prescription · Approval202503272
MFDS drugZepitor Tab. 10/5mg2025-11-27
Drug · Prescription · Approval202503099
MFDS drugExone Plus Tab. 10/160/12.5mg2025-11-18
Drug · Prescription · Approval202502989
MFDS drugExone Plus Tab. 10/160/25mg2025-11-18
Drug · Prescription · Approval202502990
MFDS drugExone Plus Tab. 5/160/12.5mg2025-11-18
Drug · Prescription · Approval202502991
MFDS drugExone Plus Tab. 5/80/12.5mg2025-11-18
Drug · Prescription · Approval202502992

Show 68 more

MFDS drugGinkgo.N Tab. 240mg2024-11-15
Drug · OTC · Notification202402698
MFDS drugDapa.N Jenta Tab. 10/5mg2024-04-22
Drug · Prescription · Approval202400937
MFDS drugLina N Duo XR Tab. 5/1000mg2024-03-18
Drug · Prescription · Approval202400568
MFDS drugLina N Duo XR Tab. 2.5/1000mg2024-03-18
Drug · Prescription · Approval202400570
MFDS drugExone-R Tablet 5/80/2.5mg2023-09-25
Drug · Prescription · Approval202302824
MFDS drugExone-R Tablet 5/160/2.5mg2023-09-25
Drug · Prescription · Approval202302825
MFDS drugOmapplusone Inj.2023-09-07
Drug · Prescription · Approval202302670
MFDS drugOmapplusone Peri Inj.2023-09-07
Drug · Prescription · Approval202302671
MFDS drugDapa N Met XR Tab. 10/500mg2023-06-21
Drug · Prescription · Approval202301905
MFDS drugDapa.N Sita Tab. 10/100mg2023-06-20
Drug · Prescription · Approval202301872
MFDS drugK-CAB ODT 25mg2023-02-28
Drug · Prescription · Approval202300722
MFDS drugRovazet tab. 10/2.5mg2023-02-10
Drug · Prescription · Approval202300508
MFDS drugDapa.N Tab. 10mg2023-01-30
Drug · Prescription · Approval202300388
MFDS drugDapa N Met XR Tab. 10/1000mg2023-01-06
Drug · Prescription · Approval202300145
MFDS drugDapa N Duo XR Tab. 10/500mg2022-11-08
Drug · Prescription · Approval202204037
MFDS drugDapa N Duo XR Tab. 5/500mg2022-11-08
Drug · Prescription · Approval202204038
MFDS drugAkynzeo injectionRevoked2022-10-31
Drug · Prescription · Approval202203950
MFDS drugK-CAB Tab. 25mg2022-07-20
Drug · Prescription · Approval202203018
MFDS drugK-CAB ODT 50mg2022-02-09
Drug · Prescription · Approval202200635
MFDS drugSugamadeon. Inj.2022-02-07
Drug · Prescription · Approval202200582
MFDS drugDapa N Duo XR Tab. 10/1000mg2021-10-08
Drug · Prescription · Approval202106824
MFDS drugDapa N Duo XR Tab. 5/1000mg2021-10-08
Drug · Prescription · Approval202106825
MFDS drugKremezin IDT2021-08-27
Drug · Prescription · Approval202106217
MFDS druginno.N Empagliflozin Tab. 25mgRevoked2021-08-04
Drug · Prescription · Approval202105730
MFDS druginno.N Empagliflozin Tab. 10mgRevoked2021-08-04
Drug · Prescription · Approval202105731
MFDS druginno.N Linagliptin 5mg Tab.Revoked2021-02-23
Drug · Prescription · Approval202101799
MFDS drugZepitor Tab. 10/10mg2021-01-08
Drug · Prescription · Approval202100240
MFDS drugZepitor Tab. 10/40mg2021-01-08
Drug · Prescription · Approval202100241
MFDS drugZepitor Tab. 10/20mg2021-01-08
Drug · Prescription · Approval202100242
MFDS drugExone-A Tab. 5/80/20mg2020-07-24
Drug · Prescription · Approval202005383
MFDS drugExone-A Tab. 5/80/10mg2020-07-24
Drug · Prescription · Approval202005384
MFDS drugExone-A Tab. 5/160/20mg2020-07-24
Drug · Prescription · Approval202005385
MFDS drugExone-A Tab. 5/160/10mg2020-07-24
Drug · Prescription · Approval202005386
MFDS drugTamlostar SR Tab. 0.4mg2020-04-17
Drug · Prescription · Approval202002721
MFDS drugK-Famcier Tab. 250mg2020-02-18
Drug · Prescription · Approval202001088
MFDS drugK-Tasol LotionRevoked2019-11-23
Drug · Prescription · Notification201908055
MFDS drugFlucle Powder 75mg2019-10-28
Drug · Prescription · Approval201907510
MFDS drugFlucle Powder 45mg2019-10-28
Drug · Prescription · Approval201907511
MFDS drugFlucle Powder 30mg2019-10-28
Drug · Prescription · Approval201907512
MFDS drugK-Tasol OintmentRevoked2019-10-17
Drug · Prescription · Notification201907327
MFDS drugK-Rolfine Nail LacquerRevoked2019-09-09
Drug · OTC · Notification201906373
MFDS drugK-Zerotasone CreamRevoked2019-08-06
Drug · Prescription · Notification201905524
MFDS drugK-Tasol SolutionRevoked2019-07-24
Drug · Prescription · Notification201905279
MFDS drugCilo K CR Cap. 200mg2019-05-31
Drug · Prescription · Approval201903667
MFDS drugCilo K CR Cap. 100mg2019-05-31
Drug · Prescription · Approval201903668
MFDS drugExone-R Tab. 5/80/5mg2019-04-15
Drug · Prescription · Approval201902300
MFDS drugExone-R Tab. 5/80/10mg2019-04-15
Drug · Prescription · Approval201902301
MFDS drugExone-R Tab. 5/160/10mg2019-04-15
Drug · Prescription · Approval201902302
MFDS drugExone-R Tab. 5/160/5mg2019-04-15
Drug · Prescription · Approval201902303
MFDS drugAcetphen Premix Inj.2018-11-07
Drug · Prescription · Notification201804429
MFDS drugFlucle Cap. 75mg2018-10-31
Drug · Prescription · Approval201804340
MFDS drugErdokle Cap.2018-09-07
Drug · OTC · Notification201803649
MFDS drugAtomet XR Tab. 10/1000mg2018-08-16
Drug · Prescription · Approval201803343
MFDS drugK-CAB Tab. 50mg2018-07-05
Drug · Prescription · Approval201802815
MFDS drugAkynzeo Cap.2018-06-28
Drug · Prescription · Approval201802685
MFDS drugAtomet XR Tab. 20/500mg2018-05-10
Drug · Prescription · Approval201801995
MFDS drugAtomet XR Tab. 20/750mg2018-05-10
Drug · Prescription · Approval201801996
MFDS drugAtomet XR Tab. 10/750mg2018-05-10
Drug · Prescription · Approval201801997
MFDS drugAtomet XR Tab. 10/500mg2018-05-10
Drug · Prescription · Approval201801998
MFDS drugAmocombi Duo Tab. 500mg2017-09-28
Drug · Prescription · Approval201707301
MFDS drugKabalin Caps. 300mg2017-07-31
Drug · Prescription · Approval201706372
MFDS drugFinasteride Tab. 1mg inno.N2017-07-20
Drug · Prescription · Approval201705805
MFDS drugAmocombi Duo Syr.2017-07-07
Drug · Prescription · Notification201705469
MFDS druginno.N Finasteride Tab. 5mg2017-06-22
Drug · Prescription · Approval201704723
MFDS druginno.N Clopidgrel Tab.2017-06-05
Drug · Prescription · Approval201703070
MFDS drugKabalin Cap. 50mg2017-05-29
Drug · Prescription · Approval201702673
MFDS drugKabalin Cap. 25mg2017-05-29
Drug · Prescription · Approval201702674
MFDS drugVesistar Tab. 5mg2017-03-31
Drug · Prescription · Approval201701572

Showing the 80 most recent of 266 records.

Clinical trials

data.go.kr

109 MFDS clinical trial authorisations · 2012–2026 (Phase 1 70 · Phase 3 19 · Bioequivalence 13 · Phase 2 6 · Phase 3a 1)

Phase 1IN-1124202026-06-19
Phase 2IN-2079072026-06-04
4 trial sites
Phase 1IN-1124202026-04-30
BioequivalenceIN-G000072026-03-13
2 trial sites
BioequivalenceIN-M000072025-09-19
2 trial sites
Phase 1IN-M00002정2025-09-10
2 trial sites
Phase 3IN-B00009주2025-08-04
17 trial sites
Phase 3IN-B00009주2025-05-07
25 trial sites
Phase 2IN-1153142025-03-12
13 trial sites
Phase 1IN-1141992024-08-29
2 trial sites
BioequivalenceIN-G000022024-04-19
2 trial sites
Phase 1IN-1124202023-11-09

Show 68 more

Phase 1IN-1124202023-09-18
Phase 1IN-C0042023-02-22
2 trial sites
Phase 1IN-1124202022-11-17
Phase 1IN-1153142022-11-15
5 trial sites
Phase 2IN-1124202022-11-14
3 trial sites
BioequivalenceIN-C0332022-07-06
2 trial sites
Phase 1IN-1124202022-04-11
Phase 1IN-C0292022-01-27
2 trial sites
BioequivalenceIN-C0342021-12-20
2 trial sites
BioequivalenceIN-C0332021-12-17
2 trial sites
Phase 3IN-C0062021-12-08
7 trial sites
Phase 3IN-C0062021-10-26
7 trial sites
Phase 1IN-1153142021-08-10
1 trial site
Phase 1IN-B009주2021-07-22
4 trial sites
Phase 1IN-C0052021-07-05
3 trial sites
Bioequivalence텔미원정80밀리그램2021-07-02
2 trial sites
Bioequivalence텔미원플러스정80/12.5밀리그램2021-06-29
2 trial sites
Phase 1IN-1153142021-06-22
1 trial site
Phase 1IN-1153142021-06-09
1 trial site
BioequivalenceIN-C0102021-05-12
1 trial site
Bioequivalence로바젯정10/20밀리그램2021-05-03
1 trial site
Bioequivalence로바젯정10/20밀리그램2020-10-30
1 trial site
Bioequivalence이노엔로자탄정100밀리그램2020-10-29
2 trial sites
Phase 1IN-C0042020-10-23
1 trial site
Phase 1IN-C0042020-10-22
1 trial site
Phase 3IN-1124202020-10-07
4 trial sites
Phase 1IN-1124202020-07-31
Phase 1IN-A0122020-06-10
2 trial sites
Phase 1IN-B0012020-06-08
1 trial site
Phase 1IN-C0052020-05-25
1 trial site
Phase 1IN-1124202020-05-11
2 trial sites
Phase 1IN-1124202020-04-02
Phase 1IN-1153142019-11-25
1 trial site
Bioequivalence로바젯정10/20밀리그램2019-11-04
1 trial site
Phase 1IN-1124202019-10-31
Phase 1IN-1124202019-10-25
1 trial site
Phase 1IN-C0092019-10-14
1 trial site
Phase 3aIN-1124202019-08-29
Phase 1CJ-400102019-06-10
1 trial site
Phase 1IN-1124202019-04-03
Phase 1CJ-300742019-03-28
1 trial site
Phase 1IN-1124202019-01-17
Phase 1IN-1141992018-11-14
1 trial site
Phase 1IN-1124202018-11-07
Phase 1IN-1124202018-11-06
Phase 1CJ-300702018-10-19
1 trial site
Phase 1CJ-300602018-09-14
1 trial site
Phase 1CJ-300752018-09-10
1 trial site
Phase 1CJ-300752018-09-10
1 trial site
Phase 1CJ-300742018-09-07
1 trial site
Phase 1IN-1124202018-04-09
Phase 3IN-1124202018-02-07
4 trial sites
Phase 1CJ-300602018-02-01
1 trial site
Phase 1CJ-300562017-11-29
1 trial site
Phase 1IN-1124202017-09-18
Phase 3CJ-300612017-06-21
18 trial sites
Phase 3CJ-400012017-02-27
1 trial site
Phase 3CJ-400012017-02-27
1 trial site
Phase 3IN-1124202016-11-30
5 trial sites
Phase 3IN-1124202016-09-26
9 trial sites
Phase 1CJ-300612016-07-27
1 trial site
Phase 1IN-1124202016-04-29
Phase 3IN-1124202016-02-18
4 trial sites
Phase 3IN-1124202015-12-15
11 trial sites
Phase 3CJ-300602015-12-03
20 trial sites
Phase 1씨제이테노포비르정(가칭)2015-11-05
1 trial site
Phase 1CJ-300612015-07-30
1 trial site
Phase 1CJ-300592015-07-27
1 trial site

Showing the 80 most recent of 109 records.

R&D and key agreements

Source: DART corporate disclosure

케이캡 적응증 확장 · 위식도역류질환 · 임상3상(한국), 허가심사중(미국)

JAK-1 저해제(사람용) · 자가면역질환(아토피) · 임상2상(한국), 임상1상 IND준비(미국)

JAK-1 저해제(반려동물용) · 아토피 · 임상3상(한국)

근감소증 치료제 · 근감소증 · 임상2상 IND신청(한국) · Co-research program

IBAT 저해제 · 변비 · 임상1상 완료(한국)

데노수맙 바이오시밀러 · 골다공증 · 품목허가 승인(한국, 유럽) · In-licensed program (2022)

항암 바이오시밀러 · 항암 · 개발사 임상1상·3상(글로벌) · In-licensed program (2025)

GLP-1RA 주사제 · 비만, 당뇨 · 임상3상(한국) · In-licensed program (2024)

두창예방백신 · 3세대두창 · 임상1상 IND준비(한국)

AI reads

MAA server logs · IP-verified

Read to answer a question

Someone asked an AI a question, and it fetched this page live to answer.

Crawled for indexing

Collected for later use. Not a signal of interest.

0answer

index 2

Last 7 days

0answer

index 2

Last 30 days

0answer

index 2

All time

OpenAIOAI-SearchBot2

Measured since Aug 25, 2026 · 1 AI engines · last read Aug 25, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.

Connect this index to your AI tool →

Not yet compiled: business overview. Send us materials and we will add them

Company facts

Founded: 2014
Listed: 2021
Market: KOSDAQ 195940
CEO: 곽달원
Location: Chungbuk
Category: Pharma & CDMO

Performance

Separate · DART

Year	Revenue	Op. profit
2025	₩1063.2B	₩110.9B
2024	₩897.1B	₩88.2B
2023	₩828.9B	₩65.9B

AI visibility

2026-08-13

70/ 100

✓Crawler access

✗Structured data

✗Sitemap

✓HTTPS

✓English pages

✗llms.txt

Keywords

pharmaceuticalgerdbiosimilarglp-1consumer-healthkosdaq

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Boditech Med Inc.1 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

Boryung Corporation1 shared

Founded in 1963 and listed in 1988, Boryung is a pharmaceutical and CDMO firm built around its antihypertensive drug Kanarb.

DIO Corporation1 shared

DIO Corporation, established in 1988 and listed on KOSDAQ in 2000, manufactures and sells dental implants.

DongBang Medical Co., Ltd.1 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

HUMASIS CO., LTD.1 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

JPI Healthcare Co., Ltd.1 shared

JPI Healthcare, founded 1980, makes X-ray imaging device components and equipment, listed on KOSDAQ in August 2025.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

SHINHUNG CO.,LTD1 shared

Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Sources and updates

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
AI visibility: Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition